BPC October 13 update

Eli Lilly LLY Approval; Rezolute RZLT -16% PM Offering

Pre-Market Updates

Eli Lilly (NYSE: LLY) announced the FDA approved Verzenio (abemaciclib) for the treatment of HR+/HER2- early breast cancer.

Rezolute, Inc. (NASDAQ: RZLT) announced that it will undergo a public offering of stock at $6.50 a share and warrants, for total proceeds of $55 million. Shares are trading down 16% at $6.40 during the pre-market.

NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) announced that an independent Data Monitoring Committee (DMC) reviewed safety data from its Phase 2/3 trial of ANA001 to treat COVID-19, recommending the continuation of the trial without modification. Shares are trading up 24% at $2.29 during the pre-market.

Revance Therapeutics, Inc. (NASDAQ: RVNC) responded to the public posting of an 483 Form, stating that its Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection remains under FDA review. Shares are trading up 13% at $23.00 during the pre-market.

Pre-Market Advancers

CompanyPriceChange
VIRX
Viracta Therapeutics Inc.
$6.70+0.59  +9.66%
ATHA
Athira Pharma Inc.
$10.54+0.91  +9.45%
YMTX
Yumanity Therapeutics Inc.
$9.75+0.64  +7.03%
CBIO
Catalyst Biosciences Inc.
$3.69+0.17  +4.83%
DBTX
Decibel Therapeutics Inc.
$7.71+0.33  +4.47%
BSGM
BioSig Technologies Inc.
$2.59+0.11  +4.44%
MDNA
Medicenna Therapeutics Corp.
$2.64+0.11  +4.35%
IMNM
Immunome Inc.
$18.86+0.7225  +3.98%
SEEL
Seelos Therapeutics Inc.
$2.36+0.09  +3.96%
PALI
Palisade Bio Inc.
$2.91+0.11  +3.93%

Pre-Market Decliners

CompanyPriceChange
MTCR
Metacrine Inc.
$1.74-2.09  -54.57%
OCUL
Ocular Therapeutix Inc.
$7.84-2.99  -27.61%
AGEN
Agenus Inc.
$4.02-1.11  -21.64%
LVTX
LAVA Therapeutics N.V.
$6.21-0.94  -13.15%
SESN
Sesen Bio Inc.
$1.13-0.12  -9.60%
BFRA
Biofrontera AG
$5.10-0.405  -7.36%
PROG
Progenity Inc.
$2.33-0.17  -6.80%
HRMY
Harmony Biosciences Holdings Inc.
$38.04-2.71  -6.65%
ADMP
Adamis Pharmaceuticals Corporation
$1.08-0.07  -6.09%
BNTC
Benitec Biopharma Inc.
$3.50-0.22  -5.91%